Postmarketing multicenter open-label controlled non-interventional clinical observation to study the corrective potential of the dietary supplement Erholiv in patients with metabolic-associated liver disease
Ukrainian Therapeutical Journal · 31.03.2026 · (1) · 33-42
DOI: 10.30978/utj2026-1-33 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ukrainian Therapeutical Journal, online erschienen am 31.03.2026. Verfasst von G. D. Fadieienko und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).
Abstract (Originalsprache)
Objective — to study the corrective potential of the dietary supplement Erholiv in patients with metabolic‑associated liver disease (MASLD). Materials and methods. 120 patients with MASLD combined with insulin resistance/type 2 diabetes mellitus and arterial hypertension of I — II degree were examined, who were divided into two groups according to baseline indicators: 1) the control group (60 patients) received recommendations for diet therapy (Mediterranean type of diet) and correction of physical activity, 2) the main group (60 patients) — in addition to diet therapy and correction of physical activity, took the dietary supplement Erholiv 1 sachet twice a day for 30 days. The study design included two visits (visit 1 — the beginning of observation, visit 2 (on day 30) — the end of observation). During the visits, somatic parameters and laboratory tests were assessed. Questionnaires were used (score assessment of the severity of the main symptoms of MASLD; assessment of the fatigue level using the Fatigue Assessment Scale (FAS); score assessment of the reduction in symptoms of concomitant diseases (type 2 diabetes mellitus, arterial hypertension of I — II degree); score assessment of the tolerability of the dietary supplement Erholiv by patients; score assessment of the possible relationship of adverse reactions with the appointment of Erholiv; assessment of the quality of life depending on the state of health using the Health‑related quality of life (HRQOL) questionnaire; assessment of the dynamics of somatic parameters, liver test indicators and blood lipid spectrum). Results. After treatment with the addition of Erholiv, a significant reduction in the clinical symptoms of MASLD was found compared to the indicators before treatment (p
Zitieren
APA
Fadieienko, G. D., Skrypnyk, I. M., Nikiforova, Y. V., & Maslova, G. S. (2026). Postmarketing multicenter open-label controlled non-interventional clinical observation to study the corrective potential of the dietary supplement Erholiv in patients with metabolic-associated liver disease. Ukrainian Therapeutical Journal, 33-42. https://doi.org/10.30978/utj2026-1-33
Vancouver
Fadieienko GD, Skrypnyk IM, Nikiforova YV, Maslova GS. Postmarketing multicenter open-label controlled non-interventional clinical observation to study the corrective potential of the dietary supplement Erholiv in patients with metabolic-associated liver disease. Ukrainian Therapeutical Journal. 2026:33-42. doi:10.30978/utj2026-1-33
BibTeX
@article{Fadieienko2026,
author = {Fadieienko, G. D. and Skrypnyk, I. M. and Nikiforova, Y. V. and Maslova, G. S.},
title = {Postmarketing multicenter open-label controlled non-interventional clinical observation to study the corrective potential of the dietary supplement Erholiv in patients with metabolic-associated liver disease},
journal = {Ukrainian Therapeutical Journal},
year = {2026},
number = {1},
pages = {33--42},
doi = {10.30978/utj2026-1-33}
}
EUVIMED